TBPH · As filed with the SEC
Theravance Biopharma balance sheet, by quarter
The statement as Theravance Biopharma presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED BALANCE SHEETS · USD
| USD | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 |
|---|---|---|---|---|
| Current assets: | ||||
| Cash and cash equivalents | 219,766,000 | 288,101,000 | 167,806,000 | 174,773,000 |
| Short-term marketable securities | 167,891,000 | 106,565,000 | 147,551,000 | 154,907,000 |
| Receivables from collaborative arrangements | 20,381,000 | 15,584,000 | 45,539,000 | 18,267,000 |
| Receivables from milestones and royalty assets | — | — | 50,000,000 | — |
| Other prepaid and current assets | 8,624,000 | 7,384,000 | 7,564,000 | 6,750,000 |
| Total current assets | 416,662,000 | 417,634,000 | 418,460,000 | 354,697,000 |
| Long-term marketable securities | — | — | 11,128,000 | 3,029,000 |
| Property and equipment, net | 5,169,000 | 5,539,000 | 5,895,000 | 6,257,000 |
| Operating lease assets | 21,926,000 | 23,001,000 | 24,371,000 | 25,450,000 |
| Future contingent milestone and royalty assets | — | — | — | 0 |
| Restricted cash | 836,000 | 836,000 | 836,000 | 836,000 |
| Other assets | 25,177,000 | 25,303,000 | 24,880,000 | 25,191,000 |
| Total assets | 469,770,000 | 472,313,000 | 485,570,000 | 415,460,000 |
| Current liabilities: | ||||
| Accounts payable | 652,000 | 1,100,000 | 2,568,000 | 2,213,000 |
| Accrued personnel-related expenses | 7,825,000 | 8,730,000 | 12,592,000 | 10,330,000 |
| Accrued clinical and development expenses | 2,395,000 | 2,396,000 | 3,373,000 | 5,842,000 |
| Accrued general and administrative expenses | 8,816,000 | 2,522,000 | 2,052,000 | 2,699,000 |
| Operating lease liabilities | 10,795,000 | 10,752,000 | 10,945,000 | 10,914,000 |
| Income tax payable | — | 5,287,000 | 5,287,000 | 4,074,000 |
| Other accrued liabilities | 283,000 | 988,000 | 1,485,000 | 1,335,000 |
| Total current liabilities | 30,766,000 | 31,775,000 | 38,302,000 | 37,407,000 |
| Long-term operating lease liabilities | 27,774,000 | 29,752,000 | 31,758,000 | 33,681,000 |
| Future royalty payment contingency | 32,795,000 | 32,795,000 | 32,795,000 | 32,213,000 |
| Unrecognized tax benefits | — | — | — | 79,165,000 |
| Unrecognized tax benefits | 88,486,000 | 87,153,000 | 85,679,000 | — |
| Other long-term liabilities | 244,000 | 244,000 | 313,000 | 313,000 |
| Shareholders' Equity | ||||
| Ordinary shares, $0.00001 par value per share: 200,000 shares authorized; 51,891 and 51,069 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 1,000 | 1,000 | 1,000 | 1,000 |
| Additional paid-in capital | 1,160,238,000 | 1,155,215,000 | 1,156,288,000 | 1,153,299,000 |
| Accumulated other comprehensive income (loss) | (76,000) | (62,000) | 61,000 | 32,000 |
| Accumulated deficit | (870,458,000) | (864,560,000) | (859,627,000) | (920,651,000) |
| Total shareholders' equity | 289,705,000 | 290,594,000 | 296,723,000 | 232,681,000 |
| Total liabilities and shareholders' equity | 469,770,000 | 472,313,000 | 485,570,000 | 415,460,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.